The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling
Abstract
BACKGROUND: Low-density lipoprotein (LDL) is internalized into cells mainly through LDLR (LDL receptor)–mediated endocytosis. In an acidic endosome, LDLR is released from LDL and recycles back to the cell surface, whereas LDL is left in the endosome and degraded in the lysosome. Circulating PCSK9 (proprotein convertase subtilisin/kexin 9) binds with LDLR and is internalized into the endosome, similar to LDL. In an acidic endosome, LDLR fails to disassociate from PCSK9, and both proteins are degraded in the lysosome. PCSK9 inhibitors are widely used for treating hypercholesterolemia. However, how PCSK9 diverts LDLR to the lysosome for degradation remains elusive. Some patients are resistant to PCSK9 inhibitors, for unknown reasons. METHODS: Both in vitro and in vivo approaches were used to investigate the molecular and cellular mechanisms of PCSK9-mediated LDLR degradation. LDLR containing FH sequence variations was expressed in Ldlr knockout mice and knockout HuH7 cells to evaluate their response to PCSK9 and PCSK9 inhibitors. RESULTS: Acidic pH induces a conformational change in LDLR extracellular domain and promotes its interaction with SNX17 (sorting nexin 17) through the intracellular domain. Knocking down SNX17 abolishes LDLR recycling and causes accelerated degradation in the lysosome. PCSK9 prevents the acidic pH–induced conformational change in LDLR and blocks its interaction with SNX17. Knocking down SNX17 abolishes PCSK9-mediated LDLR degradation. Any FH sequence variations that disrupt LDLR recycling are unresponsive to PCSK9 or PCSK9 inhibitors, even though they can internalize LDL. CONCLUSIONS: PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling. Patients with sequence variations in FH leading to defects in LDLR recycling are resistant to PCSK9 inhibitors. Genetic diagnosis and alternative drugs independent of LDLR will be needed for treatment of these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Maxfield, F. R., & McGraw, T. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1315 · Cited by 1,729
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
du Sert, N. P., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15193 · Cited by 1,137
Molecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788
Stauffer, T. P., Ahn, S., & Meyer, T. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70135-6 · Cited by 761
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review
Austin, M. A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh236 · Cited by 657
Synchronization of secretory protein traffic in populations of cells
Boncompain, G., Divoux, S., Gareil, N., de Forges, H., Lescure, A., Latreche, L., Mercanti, V., Jollivet, F., Raposo, G., & Perez, F. (2012) · Nature Methods · doi:10.1038/nmeth.1928 · Cited by 630
Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts
Basu, S. K., Goldstein, J. L., Anderson, R. G. W., & Brown, M. S. (1981) · Cell · doi:10.1016/0092-8674(81)90340-8 · Cited by 589
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Structure of the LDL Receptor Extracellular Domain at Endosomal pH
Rudenko, G., Henry, L., Henderson, K., Ichtchenko, K., Brown, M. S., Goldstein, J. L., & Deisenhofer, J. (2002) · Science · doi:10.1126/science.1078124 · Cited by 482
Familial hypercholesterolaemia
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., & Wierzbicki, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.93 · Cited by 453
Maxwell, K. N., Fisher, E. A., & Breslow, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409736102 · Cited by 415
Atypical angiopoietin-like protein that regulates ANGPTL3
Quagliarini, F., Wang, Y., Kozlitina, J., Grishin, N. V., Hyde, R., Boerwinkle, E., Valenzuela, D. M., Murphy, A. J., Cohen, J. C., & Hobbs, H. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217552109 · Cited by 409
Self-citationEndosomal sorting and signalling: an emerging role for sorting nexins
Cullen, P. J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2427 · Cited by 404
Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
Raal, F. J., & Santos, R. D. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.019 · Cited by 349
Stein, E. A., Honarpour, N., Wasserman, S. M., Xu, F., Scott, R., & Raal, F. J. (2013) · Circulation · doi:10.1161/circulationaha.113.004678 · Cited by 300
ARH Is a Modular Adaptor Protein That Interacts with the LDL Receptor, Clathrin, and AP-2
He, G., Gupta, S., Yi, M., Michaely, P., Hobbs, H. H., & Cohen, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208539200 · Cited by 232
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
Zhang, D.-W., Garuti, R., Tang, W.-J., Cohen, J. C., & Hobbs, H. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806312105 · Cited by 208
SNX17 protects integrins from degradation by sorting between lysosomal and recycling pathways
Steinberg, F., Heesom, K. J., Bass, M. D., & Cullen, P. J. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201111121 · Cited by 206
Leitersdorf, E., van der Westhuyzen, D. R., Coetzee, G. A., & Hobbs, H. H. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114258 · Cited by 205
CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL
Bartuzi, P., Billadeau, D. D., Favier, R., Rong, S., Dekker, D., Fedoseienko, A., Fieten, H., Wijers, M., Levels, J. H., Huijkman, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms10961 · Cited by 205
Phosphoinositide conversion in endocytosis and the endolysosomal system
Wallroth, A., & Haucke, V. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.000629 · Cited by 195
Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189
Self-citationPlasma PCSK9 preferentially reduces liver LDL receptors in mice
Grefhorst, A., McNutt, M. C., Lagace, T. A., & Horton, J. D. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800027-jlr200 · Cited by 183
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia
Blom, D. J., Harada‐Shiba, M., Rubba, P., Gaudet, D., Kastelein, J. J. P., Charng, M., Pordy, R. C., Donahue, S., Ali, S., Dong, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.027 · Cited by 171
Sorting nexin 17 facilitates LRP recycling in the early endosome
van Kerkhof, P., Lee, J., McCormick, L., Tetrault, E., Lu, W., Schoenfish, M., Oorschot, V., Strous, G. J., Klumperman, J., & Bu, G. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600756 · Cited by 148
Stockinger, W., Sailler, B., Strasser, V., Recheis, B., Fasching, D., Kahr, L., Schneider, W. J., & Nimpf, J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf435 · Cited by 130
Fedoseienko, A., Wijers, M., Wolters, J. C., Dekker, D., Smit, M., Huijkman, N., Kloosterhuis, N., Klug, H., Schepers, A., Willems van Dijk, K., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312004 · Cited by 126
Management of patients with familial hypercholesterolaemia
Reiner, Ž. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.92 · Cited by 106
Thedrez, A., Blom, D. J., Ramin-Mangata, S., Blanchard, V., Croyal, M., Chemello, K., Nativel, B., Pichelin, M., Cariou, B., Bourane, S., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310217 · Cited by 105
Wang, Y., Huang, Y., Hobbs, H. H., & Cohen, J. C. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m028563 · Cited by 104
Self-citationJang, H., Lee, S. E., Yang, J., Lee, H.-C., Shin, D., Lee, H., Lee, J., Jin, S., Kim, S., Lee, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz566 · Cited by 100
Garuti, R., Jones, C., Li, W.-P., Michaely, P., Herz, J., Gerard, R. D., Cohen, J. C., & Hobbs, H. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509394200 · Cited by 91
Structures of LRP2 reveal a molecular machine for endocytosis
Beenken, A., Cerutti, G., Brasch, J., Guo, Y., Sheng, Z., Erdjument‐Bromage, H., Aziz, Z., Robbins-Juarez, S. Y., Chavez, E. Y., Ahlsén, G., et al. (2023) · Cell · doi:10.1016/j.cell.2023.01.016 · Cited by 85
Burden, J. J., Sun, X.-M., García, A. B. G., & Soutar, A. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313689200 · Cited by 82
Scotti, E., Calamai, M., Goulbourne, C. N., Zhang, L., Hong, C., Lin, R. R., Choi, J., Pilch, P. F., Fong, L. G., Zou, P., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01716-12 · Cited by 81
The hepatic WASH complex is required for efficient plasma LDL and HDL cholesterol clearance
Wijers, M., Zanoni, P., Liv, N., Vos, D. Y., Jäckstein, M. Y., Smit, M., Wilbrink, S., Wolters, J. C., van der Veen, Y. T., Huijkman, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126462 · Cited by 44
Galicia-Garcia, U., Benito-Vicente, A., Uribe, K. B., Jebari, S., Larrea-Sebal, A., Alonso-Estrada, R., Aguilo-Arce, J., Ostolaza, H., Palacios, L., & Martin, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58734-9 · Cited by 44
Han, F., Liu, X., Chen, C., Liu, Y., Du, M., Guan, Y., Zhang, Y., Wang, D., Ahmed, M., Li, X., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0303-z · Cited by 43
Self-citationTang, X., Chen, R., Mesias, V. S. D., Wang, T., Wang, Y., Poljak, K., Fan, X., Miao, H., Hu, J., Zhang, L. N., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113991119 · Cited by 41
Self-citationPCSK9-targeted therapies: present and future approaches
Rifai, M. A., & Ballantyne, C. M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00634-0 · Cited by 36
Susan-Resiga, D., Girard, E., Kiss, R. S., Essalmani, R., Hamelin, J., Asselin, M.-C., Awan, Z., Butkinaree, C., Fleury, A., Soldera, A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769430 · Cited by 35
Fu, T., Guan, Y., Xu, J., & Wang, Y. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.05.002 · Cited by 25
Self-citationA point mutation of low‐density‐lipoprotein receptor causing rapid degradation of the receptor
Miyake, Y., Tajima, S., Funahashi, T., Yamamura, T., & Yamamoto, A. (1992) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1992.tb17383.x · Cited by 19
Strøm, T. B., Tveten, K., Holla, Ø. L., Cameron, J., Berge, K. E., & Leren, T. P. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.077 · Cited by 10
Zhang, Z., Yang, R., Zhu, J., Yang, X., Luo, H., Wang, H., & Luo, X. (2024) · Clinical Case Reports · doi:10.1002/ccr3.8498 · Cited by 8
Flagged first, then by citations
Research works printed but not linked: 2
- 10.1016/j.bbalip.2017.05.002 · DOI · Paper page
- 10.1194/jlr.m028563 · DOI · Paper page
Cited by
Sorted by citations
Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 14
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 12
Asialoglycoprotein receptor 1: a multifaceted receptor in the liver and cardiovascular system
Xiao, X., Nie, Y., & Leng, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1653452 · Cited by 11
He, Z., Zhang, L., Gong, S., Yang, X., & Xu, G. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5667 · Cited by 11
Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics
Zhu, B. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020634 · Cited by 11
Potential Roles of SNX17, Rab11, and Rab5 in LDLR Recycling
Zhao, X., Long, S., Zhu, M., Hao, H., Liao, Y., Zhang, C., & Liu, Z. (2025) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.125.322498 · Cited by 8
Kuang, J. C., Hao, L., Zhang, M., & Yang, Z. (2025) · MedComm · doi:10.1002/mco2.70451 · Cited by 7
Self-citationProprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future
Sabatine, M. S., & Laufs, U. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag148 · Cited by 7
Yang, Q., Liu, X., Zhang, T., Zhao, X., & 肖小河 (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s591764 · Cited by 6
Self-citationNowacka, A., Śniegocki, M., & Ziółkowska, E. (2025) · Cells · doi:10.3390/cells14181479 · Cited by 5
Abbas, G., Malik, M. N. H., Yasin, H. K. A., Alshammari, S. O., Murtaza, G., Hassan, W., Atif, M., & Shabbir, R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331356 · Cited by 4
Targeting of PCSK9 in the Management of Alzheimer's Disease: Expanding the New Potential Key Player
Alanazi, M., Al‐kuraishy, H. M., Hussain, N. R., Waheed, H. J., Al-Gareeb, A. I., Albuhadily, A. K., Waheeb, T. S., & Batiha, G. E. (2026) · Drug Development Research · doi:10.1002/ddr.70231 · Cited by 4
The Impact of IGFBP6 Knockdown on Cholesterol Metabolism in Breast Cancer Cells
Antipenko, I. D., Makarova, J. A., Shkurnikov, M. Y., & Tonevitsky, A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673396050250729132235 · Cited by 3
Advances in molecular regulation and function of LDLR family in viral infection
Yao, Q. H., Gong, J., Lu, H., Liu, W., & Ding, L. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1702637 · Cited by 3
Guo, H., Pan, L.-T., Wang, L., Huang, Z., Wu, Q., Wang, J., & Liao, Z. (2026) · Foods · doi:10.3390/foods15020332 · Cited by 3
Zheng, Y., Zheng, Y., Huang, Z., Zhang, Y., Li, J., Zhao, C., Liu, B., & Tong, A. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157170 · Cited by 3
PCSK9-promoted LDLR degradation: Recruitment or prevention of essential cofactors?
Li, R., Zhang, C. X., Liu, J., & Zhang, D.-W. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100362 · Cited by 4
The Impact of PCSK9 on Diabetic Cardiomyopathy: Mechanisms and Implications
Wang, H., Wang, P., Wang, Y., Du, S., Zhao, J., & Zhang, Z. (2025) · Biomolecules · doi:10.3390/biom15091240 · Cited by 2
Self-citationLiu, L., Wu, C., Zhang, Z., Jin, X., Zou, Q., Wang, M., Huang, B., Gan, X., & Tong, J. (2025) · International Journal of COPD · doi:10.2147/copd.s526511 · Cited by 2
The Role of Sirtuins in Improving Cardiovascular Function and the Prevention of Aging
Duran, R., Parikh, M. A., Raizada, A., Frishman, W. H., & Peterson, S. J. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001140 · Cited by 2
Xiao, Q., Wang, M., Wang, S., Wang, L., & Ding, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07647-0 · Cited by 2
PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification
Zhang, X., Hao, Y., Han, D., Jin, X., Shang, X., Zhang, L., Gan, Z., Ye, W., Wang, S., Li, X., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.078830 · Cited by 2
Self-citationThe unseen impact of subclinical hypothyroidism on lipid profile and cardiovascular risk
Mawlood, M. S. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102605 · Cited by 2
Jiang, H., Huang, Z., Hu, H., Tu, J., & Luo, L. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11564-9 · Cited by 2
Wang, Y.-S., Wang, X., Chen, M., Lu, P., & Qian, Z.-L. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100280 · Cited by 1
Self-citationLi, X., Wang, Z., Liang, J., Li, B., Meng, Q., & Gao, M. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001794 · Cited by 1
Sweilam, S. H., Al-Kuraishy, H. M., Mustafa, A. M., Hassan, S. M., Alsharari, R., & Batiha, G. E. (2026) · Microvascular Research · doi:10.1016/j.mvr.2026.104925 · Cited by 1
Yang, Y., Li, X., Tang, D., Li, B., Wu, S.-J., Cao, H.-X., Zong, W., & Zhang, H.-M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073039 · Cited by 1
Exogenous Ganglioside GM3 Attenuates Atherosclerosis via Multi-Organ Modulation of Lipid Metabolism
Zhou, J., Zhuang, H., Sheng, Q., Qiu, Z., & Chen, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050547 · Cited by 1
Wang, J. D. J., Teo, A. Y. T., Xiao, B., Chao, Y., Zhou, Z. D., Tan, B. J.-W., Chan, L.-L., Rosalie, E., & Tan, E.-K. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00568-y
GPR146 regulates CYP7A1 transcription in cells and in vivo of mice
Liu, X., Han, J., Li, X., Zhang, Z., Li, J., & Yao, Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152045
Self-citationPCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report
Li, Y., Jiang, H., Xiong, Y., Yan, S., & Chen, X. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1644145
Liu, L., Li, Y., Liu, B., Li, G., Yang, C., Song, J., Cui, Q., & Zhao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003835
Dababneh, M. F., Alhasso, B., Shareef, A., Kyada, A., Malathi, H., Maharana, L., Puri, D., Gupta, H., Yarmukhamedova, N. A., Sameer, H. N., et al. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10651-6
Hnf1aos1 as a Metabolic Coordinator of Hepatic Lipid Homeostasis and Feedback Control
Armanios, B., Jin, J., Laddha, A. P., Nguyen, L. T. G., Tawfik, S. M., Mishra, N., Manautou, J. E., & Zhong, X. (2026) · Non-Coding RNA · doi:10.3390/ncrna12030015
Prevalence of clinically suspected familial hypercholesterolemia in the United States, 2009–2018
Zhao, Y., Cui, W., Wang, Z., Yun, Q., & Qiao, J. (2026) · Cardiac Research · doi:10.1097/re9.0000000000000019
Zhang, H., Shuai, D., Ruan, M., Wu, M., Wang, L., Chu, M., & Rong, X. (2026) · IUBMB Life · doi:10.1002/iub.70119
余, 文. (2026) · Traditional Chinese Medicine · doi:10.12677/tcm.2026.156322
Zou, M., Shen, C., Li, H., Liu, W., & Feng, Y. (2026) · Materials & Design · doi:10.1016/j.matdes.2026.116422
PCSK9 inhibitors do not increase cognitive risk
Ni, D., Feng, Z., Liang, D., Qi, Z., Lu, Y., Zhu, L., & Li, G. (2026) · Biology Direct · doi:10.1186/s13062-026-00865-6
Cozma, D. C., Lighezan, D., Tudoran, C., Voinescu, O. R., & Mornoş, C. (2026) · Medicina · doi:10.3390/medicina62071257
Cholesterol metabolism implications for cancer and therapy
Lin, L., Song, P., Xie, W., & Guo, J. (2026) · The Innovation Nutrition · doi:10.59717/j.xinn-nutri.2026.100025
Duan, Y., Qiu, Y., Zhu, Y., Wang, Q., Lin, J., Duan, Y., Wang, Q., & Dong, Y. (2026) · Advanced Science · doi:10.1002/advs.77100
“RAL” the LDLR to lysosomes for degradation
Guan, Y., Huang, Y., Li, Z., & Wang, Y. (2026) · Life Metabolism · doi:10.1093/lifemeta/loag025
Self-citationHadini, A., Addous, A., Baraich, A., Bendada, M., Karim, A., Choukri, M. A., Mokhtari, I., Cordazzo, R., Pétriacq, P., Amrani, S., et al. (2026) · Nutrients · doi:10.3390/nu18172766
Circulating cholesterol fuels SARS-CoV-2 replication via ORF3a
Hayashi, J. M., Taha, T. Y., Chen, I. P., Suryawanshi, R. K., Swaney, D. L., McCavitt-Malvido, M., Montaño, M., Syed, A. M., Khalid, M. M., Simoneau, C. R., et al. (2026) · EMBO Reports · doi:10.1038/s44319-026-00907-0
Li, B., Ye, C., Wang, Z., Zhang, J., Fan, Z., Huo, Y., Xianwei, W., & Lv, F. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.118047
Opazo, M. C., Gallegos, A., Muñoz, A., Zapata, R., Rivera, J. C., Sepúlveda, R. V., & Aguayo, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219676
Ding-yu, S., Li, Z.-Z., Bai, J.-Q., Dong, X., Zhang, W., Wang, H.-Y., Huang, X.-R., Dong, Z.-C., Guo, L., Lin, Q., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02475-z
Metadata
- Authors
- Guan, Y., Liu, X., Yang, Z., Zhu, X., Liu, M., Du, M., Pan, X., & Wang, Y.
- Affiliations
- Wuhan University (CN)
- Capital Normal University (CN)
- Corresponding author
- Guan, YangYang
- Liu, Xiaomin
- Yang, Zetian
- Venue
- Circulation
- Published
- 2025-05-27
- Volume
- 151
- Issue
- 21
- Pages
- 1512-1526
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4408377193
- Cited by
- 50
- References
- 50
- Citations by year
- 2026: 32 · 2025: 18
- FWCI
- 16.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- PCSK9, LDL receptor, SNX17, LDLR degradation, PCSK9 inhibitors, low pH, endosomal acidification, lysosomal degradation, hypercholesterolemia
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Animals, Endocytosis, Humans, Lysosomes, Receptors, LDL, Endosomes, Mice, Knockout, Mice, Sorting Nexins, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
